1) Wharton S, Liu A, Pakseresht A, et al. Real world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Abstract (T4PLB2) presented at the 25th European Congress on Obesity (ECO 2018), Vienna, Austria. 23-26 May 2018. 2) Wharton S, Liu A, Pakseresht A, et al. Real world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Abstract (PSY10) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018). Baltimore, USA. 19-23 May 2018. 3) Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11-22. 4) Novo Nordisk Canada. Saxenda(R) (liraglutide 3 mg) Canada Product Monograph. 12 July 2017. Available at: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-n... . Last accessed: May 2018. 5) EMA. Saxenda(R) (liraglutide 3 mg) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... . Last accessed: May 2018. 6) Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000;43:1664-1669. 7) American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://news.cision.com/american-medical-association/r/ama-ad... . Last accessed: May 2018. 8) Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:1-20. 9) Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096. 10) Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918. 11) Li C, Ford ES, Zhao G, et al. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. Prev Med. 2010;51:18-23. 12) Morandi A, Maffeis C. Urogenital complications of obesity. Best Pract Res Clin Endocrinol Metab. 2013;27:209-218. 13) Angulo P. Nonalchoholic fatty liver disease N Engl J Med. 2009;346:1221-1231. 14) Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-2366. 15) Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755-765. 16) Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307:1909-1914. 17) Tanaka T. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. Am J Clin Nutr. 2013;97:1395-1402. 18) Woods SC. Understanding the physiology of obesity: review of recent developments in obesity research. Int J Obes Relat Metab Disord. 2002;26 Suppl 4:S8-S10. 19) World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheet.... Last accessed: May 2018. 20) Cawley J, Meyerhoefer C, Biener A, et al. Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status. Pharmacoeconomics. 2015;33:707-722.
Novo Nordisk A/S Corporate Affairs Novo Alle 2880 Bagsvaerd Denmark Telephone: +45-4444-8888 Internet:www.novonordisk.com [http://www.novonordisk.com ] CVR no: 24 25 67 90 Further information Media: Katrine Sperling, +45-4442-6718, krsp@novonordisk.com Asa Josefsson, +45-3079-7708, aajf@novonordisk.com Investors: Peter Hugreffe Ankersen, +45-3075-9085, phak@novonordisk.com Anders Mikkelsen, +45-3079-4461, armk@novonordisk.com Christina Kjaer, +45-3079-3009, cnje@novonordisk.com
